Profile data is unavailable for this security.
About the company
GNI Group Ltd is a Japan-based company engaged in pharmaceutical business and medical device business. The Company conducts global pharmaceutical research and development, manufacturing and distribution and biomaterials business. The Company operates in two business segments. The Pharmaceuticals segment conducts research and development, manufacturing, and sale of developed compounds, including ETUARY sold in the China market and Hydronidone (F351), which is in clinical trials. The main products also include other pharmaceuticals and reagents. The Medical Devices segment develops, manufactures, and sells medical devices such as biomaterials in the United States. This segment also includes medical device Designated Marketing Authorization Holder (DMAH) and In-Country Caretaker (ICC) services. The Company also conducts clinical and business development in the United States and conducts clinical development of F351 for Metabolic Dysfunction-Associated Steatohepatitis in the United States.
- Revenue in JPY (TTM)26.01bn
- Net income in JPY8.09bn
- Incorporated2001
- Employees843.00
- LocationGNI Group Ltd3F, Nihonbashi-Honcho YS Bldg2-2-2, Nihonbashi Hon-choCHUO-KU 103-0023JapanJPN
- Phone+81 362143600
- Fax+81 362143668
- Websitehttps://www.gnipharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Katakura Industries Co., Ltd. | 39.97bn | 3.05bn | 64.65bn | 1.04k | 19.99 | 0.8111 | 10.98 | 1.62 | 91.86 | 91.86 | 1,206.19 | 2,263.56 | 0.2879 | 2.26 | 4.70 | 38,434,620.00 | 2.33 | 2.35 | 3.05 | 3.34 | 38.45 | 37.75 | 8.09 | 8.32 | 2.57 | -- | 0.1236 | 18.81 | 16.62 | -2.04 | 8.09 | 18.87 | -7.46 | 10.76 |
| ASKA Pharmaceutical Holdings Co Ltd | 62.03bn | 6.51bn | 69.01bn | 747.00 | 9.82 | 1.06 | 7.33 | 1.11 | 230.05 | 230.05 | 2,191.75 | 2,131.76 | 0.6682 | 1.72 | 3.40 | 83,033,460.00 | 7.02 | 3.37 | 9.09 | 4.25 | 48.12 | 45.39 | 10.50 | 5.02 | 1.96 | -- | 0.1433 | 15.79 | 6.81 | 4.32 | -1.21 | 12.16 | -13.15 | 2.71 |
| ispace Inc | 1.99bn | -2.52bn | 69.10bn | 216.00 | -- | 16.66 | -- | 34.70 | -33.88 | -33.88 | 24.76 | 44.55 | 0.1476 | -- | 24.87 | 9,219,852.00 | -18.66 | -- | -32.11 | -- | 46.91 | -- | -126.42 | -- | 1.72 | -16.56 | 0.7317 | -- | 46.74 | -- | -180.75 | -- | -- | -- |
| Eiken Chemical Co Ltd | 39.90bn | 2.95bn | 81.08bn | 754.00 | 25.69 | 1.49 | 15.48 | 2.03 | 78.83 | 78.83 | 1,067.99 | 1,355.09 | 0.6013 | 2.74 | 3.07 | 52,923,080.00 | 4.44 | 8.83 | 5.45 | 11.34 | 42.67 | 46.39 | 7.38 | 12.16 | 2.95 | -- | 0.0563 | 31.24 | 0.6396 | 4.34 | -7.75 | 17.07 | 0.6216 | 15.33 |
| JCR Pharmaceuticals Co Ltd | 41.37bn | 5.36bn | 102.84bn | 879.00 | 18.54 | 1.78 | 12.56 | 2.49 | 42.78 | 42.78 | 330.47 | 445.94 | 0.4253 | 0.5492 | 3.03 | 47,059,160.00 | 5.53 | 9.63 | 8.38 | 14.67 | 74.83 | 74.34 | 12.99 | 19.32 | 1.15 | 19.24 | 0.294 | 27.35 | -32.77 | 10.77 | -74.00 | 4.20 | 53.67 | 25.21 |
| Zeria Pharmaceutical Co Ltd | 74.57bn | 8.64bn | 108.79bn | 1.73k | 10.45 | 1.15 | 6.99 | 1.46 | 195.97 | 195.97 | 1,691.65 | 1,780.16 | 0.514 | 1.44 | 3.37 | 43,130,530.00 | 5.96 | 3.37 | 9.31 | 5.40 | 73.90 | 71.45 | 11.60 | 6.52 | 0.8269 | -- | 0.3915 | 41.33 | 14.87 | 1.15 | 56.41 | 8.30 | 5.40 | 3.30 |
| Torii Pharmaceutical Co Ltd | 54.64bn | 4.12bn | 109.15bn | 583.00 | 25.86 | 0.8867 | 23.84 | 2.00 | 146.56 | 146.56 | 1,944.21 | 4,274.44 | 0.4091 | 3.03 | 2.13 | 93,718,700.00 | 3.08 | 6.52 | 3.41 | 7.35 | 45.37 | 49.55 | 7.54 | 17.98 | 6.19 | -- | 0.002 | 24.17 | 11.74 | -2.67 | 4.44 | 28.76 | -20.38 | 20.11 |
| Mochida Pharmaceutical Co Ltd | 100.09bn | 3.01bn | 116.72bn | 1.53k | 36.94 | 0.8701 | 20.24 | 1.17 | 84.34 | 84.34 | 2,768.28 | 3,579.89 | 0.6294 | 1.86 | 2.91 | 65,457,820.00 | 1.89 | 4.86 | 2.26 | 5.94 | 51.24 | 52.20 | 3.01 | 7.36 | 3.24 | -- | 0.00 | 41.96 | -6.28 | -0.6644 | -37.09 | -5.92 | 14.62 | -1.21 |
| Kyorin Pharmaceutical Co Ltd | 119.83bn | 4.26bn | 116.94bn | 2.14k | 24.38 | 0.8215 | 13.81 | 0.9759 | 74.23 | 74.23 | 2,089.34 | 2,203.28 | 0.678 | 1.34 | 2.73 | 56,047,710.00 | 2.41 | 3.20 | 3.12 | 3.93 | 42.92 | 48.72 | 3.56 | 5.10 | 1.40 | -- | 0.141 | 70.57 | 7.33 | 0.471 | 20.12 | -6.40 | 19.42 | -2.16 |
| GNI Group Ltd | 26.01bn | 8.09bn | 121.74bn | 843.00 | 15.25 | 3.60 | 12.04 | 4.68 | 160.04 | 160.04 | 531.63 | 678.01 | 0.5402 | 1.78 | 7.33 | 30,854,770.00 | 19.74 | 7.23 | 22.76 | 8.80 | 86.24 | 85.75 | 36.54 | 14.57 | 3.49 | 26.42 | 0.0931 | 0.00 | 49.32 | 38.97 | 1,981.71 | -- | 19.69 | -- |
| Takara Bio Inc | 47.67bn | 1.57bn | 122.10bn | 1.79k | 77.72 | 1.09 | 18.62 | 2.56 | 13.05 | 13.05 | 395.88 | 932.12 | 0.3795 | 1.47 | 2.58 | 26,586,730.00 | 1.27 | 11.78 | 1.38 | 13.36 | 55.32 | 63.90 | 3.34 | 20.22 | 5.81 | -- | 0.00 | 24.13 | 15.43 | 19.32 | -19.33 | 46.97 | 29.87 | 56.32 |
| Nxera Pharma Co Ltd | 12.77bn | -7.19bn | 133.72bn | 350.00 | -- | 2.00 | -- | 10.47 | -87.73 | -87.73 | 154.90 | 746.93 | 0.0995 | -- | 3.39 | 36,474,280.00 | -5.61 | -0.6588 | -6.11 | -0.7036 | 75.70 | 89.83 | -56.34 | -4.46 | 3.62 | -8.25 | 0.5254 | -- | -18.00 | -- | -1,982.98 | -- | -- | -- |
| Towa Pharmaceutical Co Ltd | 236.78bn | 11.74bn | 143.01bn | 4.30k | 11.64 | 0.9181 | 4.48 | 0.604 | 238.42 | 238.42 | 4,810.52 | 3,023.62 | 0.6134 | 1.62 | 3.73 | 55,090,510.00 | 3.04 | 4.73 | 3.80 | 6.39 | 34.66 | 41.27 | 4.96 | 8.06 | 1.48 | -- | 0.5686 | 19.97 | 26.11 | 17.46 | -86.17 | -19.46 | 14.66 | 13.63 |
| KAKEN PHARMACEUTICAL CO., LTD. | 72.10bn | 2.97bn | 155.69bn | 1.13k | 43.37 | 0.9158 | 27.23 | 2.16 | 78.14 | 78.14 | 1,915.49 | 3,700.49 | 0.429 | 1.86 | 2.89 | 63,801,770.00 | 1.76 | 8.17 | 2.00 | 9.56 | 53.89 | 55.55 | 4.11 | 16.09 | 4.68 | -- | 0.0267 | 44.04 | -4.01 | -5.81 | -43.03 | -22.17 | 3.16 | 0.00 |
| Sumitomo Pharma Co Ltd | 330.31bn | -173.72bn | 159.16bn | 6.25k | -- | 0.4626 | -- | 0.4819 | -437.26 | -437.26 | 831.40 | 864.73 | 0.2717 | 1.36 | 2.71 | 52,849,120.00 | -14.95 | 1.15 | -22.20 | 1.67 | 59.93 | 72.18 | -55.04 | 2.54 | 0.3785 | -- | 0.5452 | 41.44 | -0.8019 | 3.54 | -232.08 | -- | 0.6204 | 3.13 |
| Kissei Pharmaceutical Co Ltd | 73.72bn | 12.20bn | 174.32bn | 1.80k | 13.26 | 0.7995 | 10.54 | 2.36 | 266.51 | 266.51 | 1,612.29 | 4,421.72 | 0.3213 | 1.68 | 2.60 | 41,067,970.00 | 5.38 | 3.21 | 5.87 | 3.47 | 48.23 | 52.39 | 16.74 | 11.10 | 4.51 | -- | 0.007 | 36.56 | 3.23 | -1.83 | -18.52 | 3.08 | 3.74 | 10.76 |
Data as of Apr 26 2024. Currency figures normalised to GNI Group Ltd's reporting currency: Japanese Yen JPY
9.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Heights Capital Management, Inc.as of 20 Nov 2023 | 2.19m | 4.40% |
| FIL Investment Management (Hong Kong) Ltd.as of 29 Feb 2024 | 735.60k | 1.48% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 627.59k | 1.26% |
| Simplex Asset Management Co., Ltd.as of 04 Apr 2024 | 418.60k | 0.84% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 396.60k | 0.80% |
| Sydbank A/S (Investment Management)as of 27 Mar 2024 | 116.10k | 0.23% |
| BlackRock Advisors (UK) Ltd.as of 02 Apr 2024 | 91.60k | 0.18% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 84.20k | 0.17% |
| TIAA-CREF Investment Management LLCas of 29 Feb 2024 | 40.70k | 0.08% |
| Geode Capital Management LLCas of 29 Feb 2024 | 32.70k | 0.07% |
More ▼
Data from 31 Dec 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
